HHHildrun Haibel

Hildrun Haibel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hildrun Haibel has a total of 169 co-authors. Here are the top co-authors by number of shared publications:

  • Denis Poddubnyy

    Division of Rheumatology, Department of Medicine, University of Toronto and Schroeder Arthritis Institute, University Health Network, Toronto, Canada

    18 shared publications
  • Fabian Proft

    Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin , Berlin

    12 shared publications
  • Joachim Sieper

    Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité - Universitätsmedizin Berlin, Berlin, Germany

    8 shared publications
  • Martin Rudwaleit

    Department of Internal Medicine and Rheumatology, Medical School and University Medical Center OWL, Klinikum Bielefeld, Bielefeld University, Bielefeld, Germany

    8 shared publications
  • Mikhail Protopopov

    Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité Universitätsmedizin Berlin, Berlin, Germany

    8 shared publications
  • Valeria Rios Rodriguez

    Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin

    8 shared publications

Latest Publications

  • Open Access

    Lidödeme führen zur Diagnose einer systemischen Sarkoidose

    by Paul Jung, Thomas Schneider, Rasmus Leistner, Hildrun Haibel

  • Open Access

    Proteomic Tear Fluid Analysis in Acute Anterior Uveitis Reveals Distinct Characteristics During Active Inflammation

    by Lynn S. Zur Bonsen, Uwe Pleyer, Dominika Pohlmann, Melis C. Cömert Arisoy, Vadim Farztdinov, Hildrun Haibel, Isabel Kaeferstein, Vitus A. Knecht, Steffen E. Künzel, Michael Mülleder, et al.

    Uveitis is a potentially vision-threatening intraocular inflammation of the uvea, predominantly observed in individuals aged 20 to 60 years. Anterior uveitis (AU) — characterized by inflammation of...

  • Open Access

    Clinical and imaging characteristics of patients with axial psoriatic arthritis: Baseline findings from the GESPIC-axial-PsA cohort

    by Henriette Baum, Murat Torgutalp, Valeria Rios Rodriguez, Judith Rademacher, Mikhail Protopopov, Hildrun Haibel, Burkhard Muche, Kay-Geert Hermann, Denis Poddubnyy, Fabian Proft

    Background: Axial disease is a domain of psoriatic arthritis (PsA), referred to as axial-PsA. Despite recent advances and increasing recognition, axial-PsA remains poorly defined; validated classification criteria and longitudinal cohorts are lacking. Objectives: We aimed to characterise axial-PsA and delineate phenotypes in an imaging-confirmed cohort. Design: GESPIC-axPsA, a dedicated arm of the German Spondyloarthritis Inception Cohort (GESPIC), is a prospective, monocentric, study including patients with psoriasis and clinically diagnosed axial-PsA confirmed by imaging. Baseline assessments included clinical phenotyping, laboratory testing, biosample-collection, radiographs of the axial skeleton, and MRI of the whole spine and sacroiliac joints (SIJs). Methods: The analysis was primarily descriptive, characterizing baseline clinical and imaging features of patients with imaging-confirmed axial-PsA; categorical and continuous variables were summarized using appropriate measures based on their distribution, and subgroup comparisons were performed using chi-square or Fisher’s exact tests for categorical variables and Mann–Whitney U tests for continuous variables after assessing normality. Results: We enrolled 107 axial-PsA patients (55% female; mean age 44.8 years); 78.5% had active psoriasis, 78.6% had inflammatory back pain (IBP), and 48.6% were HLA-B27 positive. Radiographic sacroiliitis was present in 45.7%. On MRI, active/structural SIJ lesions were seen in 53.3%/73.3%; spinal active/structural lesions in 60.0%/53.3%. Both Classification criteria for axSpA (ASAS) and PsA (CASPAR) were simultaneously fulfilled in 60.7%. We identified 20 patients (18.7%) with spine-only involvement—spinal MRI lesions without SIJ lesions on radiography or MRI. Compared with the remainder, the spine-only group was older, more often female, less frequently HLA-B27–positive, and had back pain less consistent with IBP (all p<0.05). Conclusions: In our imaging-confirmed axial-PsA cohort using standardized whole-spine and SIJ MRI, we observed marked phenotypic heterogeneity. Approximately one fifth had isolated spinal involvement; this subgroup differed by age, sex, HLA-B27, and IBP features, with imaging distributions distinct from axSpA—supporting the need for disease-specific classification criteria.

  • Open Access

    Achieving inactive disease state in men and women with axial spondyloarthritis: results from a multi-country prospective observational study

    by Denis Poddubnyy, Joachim Sieper, Servet Akar, Santiago Muñoz-Fernández, Hildrun Haibel, Mikhail Protopopov, Elisabeth Altmaier, Fabiana Ganz, Robert D Inman

    Objective: To assess the probability of achieving low disease activity (LDA) and inactive disease (ID) in men vs women with recently diagnosed axial spondyloarthritis (axSpA). Methods: This 1-year post-hoc analysis of the PROOF study assessed patients with recently diagnosed (≤12 months) axSpA. Patients were classified as having radiographic (r) or non-radiographic (nr) axSpA using central radiograph readings. Demographics, disease characteristics, and treatment were assessed at baseline and annually thereafter. Disease activity at 1 year was assessed by Axial Spondyloarthritis Disease Activity Score (ASDAS). Results: 1385 patients with baseline and year 1 data were included. Patients were classified as having nr-axSpA (n = 477 [34%]; 47% men) or r-axSpA (n = 908 [66%]; 71% men). Men had higher TNF inhibitor (TNFi) use vs women with nr-axSpA (15% vs 9%; P = 0.0238) and r-axSpA (20% vs 13%; P = 0.0118). At 1 year, TNFi use increased, remaining significantly higher for men with r-axSpA (34.9% vs 28.1%; P = 0.0497) but not nr-axSpA. Significantly more men with nr-axSpA achieved ASDAS LDA (46.0% vs 27.1%; P = 0.0002) and ID (21.7% vs 9.6%; P = 0.0013); no significant difference was observed in r-axSpA. Female sex was associated with significantly lower odds of achieving LDA and ID in nr-axSpA only (odds ratio, men vs women, LDA: 2.23 [95% CI, 1.45, 3.42]; ID: 2.40 [1.39, 4.12]). Conclusion: Women with nr-axSpA, but not r-axSpA, were less likely to achieve LDA and ID after 1 year than men. These data stress the need to carefully evaluate the diagnosis and causes of pain in patients diagnosed with axSpA.


  • Open Access

    Tofacitinib in early active axial spondyloarthritis: protocol of a randomized double-blind, placebo-controlled, multicenter phase IV study, FASTLANE

    by Valeria Rios Rodriguez, Lidia Sánchez-Riera, Hildrun Haibel, Caroline Höppner, Murat Torgutalp, Fabian Proft, Judith Rademacher, Elke Binder, Annette Diehl, Ivana Vranic, et al.

    Background: Early treatment initiation is one of the strongest predictors of good treatment response in axial spondyloarthritis (axSpA). Recently, the Assessment in SpondyloArthritis International Society (ASAS) defined early axSpA as a diagnosis of axSpA with a duration of axial symptoms equal to or less than 2 years. Tofacitinib is a Janus kinase (JAK) inhibitor for the treatment of ankylosing spondylitis. Objectives: Compare the efficacy and safety of tofacitinib versus placebo (both on non-steroidal anti-inflammatory drug (NSAID) background) in patients with active early axSpA and inadequate response to at least one NSAID. Design: This is a phase IV, randomized, double-blind, placebo-controlled, multicenter clinical trial. Methods and analysis: The study will recruit 104 patients aged ⩾18 and ⩽45 years with active early axSpA (chronic back pain ⩽2 years), inadequate response to at least one NSAID, and objective signs of active inflammation (on magnetic resonance imaging (MRI) of sacroiliac joints (SIJs) or elevated C-reactive protein). Patients will be randomized 1:1 to receive tofacitinib 5 mg twice daily or placebo, with background naproxen 500 mg twice daily for 16 weeks. Patients not meeting early treatment response criteria at week 4 will receive open-label tofacitinib until week 16. Primary and key secondary endpoints at week 16 will be the proportion of patients achieving disease remission (Axial Spondyloarthritis Disease Activity Score Trial registration : ClinicalTrials.gov: NCT06112665; CTIS: 2023-505050-18-00.


  • Open Access

    Clinical information on imaging referrals for suspected or known axial spondyloarthritis: recommendations from the Assessment of Spondyloarthritis International Society (ASAS)

    by Torsten Diekhoff, Chiara Giraudo, Pedro M Machado, Michael Mallinson, Iris Eshed, Hildrun Haibel, Kay Geert Hermann, Manouk de Hooge, Lennart Jans, Anne Grethe Jurik, et al.

    Objectives This study aims to establish expert consensus recommendations for clinical information on imaging requests in suspected/known axial spondyloarthritis (axSpA), focusing on enhancing diagnostic clarity and patient care through guidelines. Materials and methods A specialised task force was formed, comprising 7 radiologists, 11 rheumatologists from the Assessment of Spondyloarthritis International Society (ASAS) and a patient representative. Using the Delphi method, two rounds of surveys were conducted among ASAS members. These surveys aimed to identify critical elements for imaging referrals and to refine these elements for practical application. The task force deliberated on the survey outcomes and proposed a set of recommendations, which were then presented to the ASAS community for a decisive vote. Results The collaborative effort resulted in a set of six detailed recommendations for clinicians involved in requesting imaging for patients with suspected or known axSpA. These recommendations cover crucial areas, including clinical features indicative of axSpA, clinical features, mechanical factors, past imaging data, potential contraindications for specific imaging modalities or contrast media and detailed reasons for the examination, including differential diagnoses. Garnering support from 73% of voting ASAS members, these recommendations represent a consensus on optimising imaging request protocols in axSpA. Conclusion The ASAS recommendations offer comprehensive guidance for rheumatologists in requesting imaging for axSpA, aiming to standardise requesting practices. By improving the precision and relevance of imaging requests, these guidelines should enhance the clinical impact of radiology reports, facilitate accurate diagnosis and consequently improve the management of patients with axSpA.


  • Reporting Sacroiliac Joint Imaging Performed for Known or Suspected Axial Spondyloarthritis: Assessment of SpondyloArthritis International Society Recommendations

    by Torsten Diekhoff, Iris Eshed, Chiara Giraudo, Hildrun Haibel, Kay Geert A. Hermann, Manouk de Hooge, Lennart Jans, Anne Grethe Jurik, Robert G. Lambert, Pedro Machado, et al.

    The consensus recommendations by the Assessment of SpondyloArthritis International Society provide a structured approach for effective communication from radiologists to rheumatologists for sacroiliac joint imaging of suspected or known axial spondyloarthritis, emphasizing the importance of detailed reporting, consideration of differential diagnoses, and expert collaboration.


  • Impact of body composition on clinical outcomes in patients with active radiographic axial spondyloarthritis under biological therapy

    by Valeria Rios Rodriguez, Murat Torgutalp, Fabian Proft, Judith Rademacher, Mikhail Protopopov, Laura Spiller, Hildrun Haibel, Joachim Sieper, Denis Poddubnyy

    Objective: To assess the association of body composition (BC), evaluated by bioimpedance analysis (BIA), with disease activity, physical function and mobility in patients with axSpA undergoing bDMARD treatment for one year. Methods: Patients with AS (radiographic axSpA) were enrolled in an extension of the German Spondyloarthritis Inception Cohort (GESPIC). Patients were required to be candidates for bDMARD therapy at baseline presenting high disease activity despite previous treatment with nonsteroidal anti-inflammatory drugs. Outcomes (disease activity, function and mobility) and BC parameters were assessed at baseline and every 6 months thereafter. The association between BC parameters and outcomes over 1 year was analysed using longitudinal generalized estimating equations. Results: Seventy-four patients with radiographic axSpA were included in current analysis with a mean age of 36.5 years, disease duration of 6.2 years and Axial Spondyloarthritis Disease Activity Score (ASDAS) of 3.4 at baseline. Fat mass value and fat mass index were positively associated with disease activity (ASDAS: ß = 0.012, 95% CI [−0.003, 0.027] and ß = 0.035, 95% CI [−0.010, 0.081], respectively) and functional disability (BASFI: ß = 0.037, 95% CI [0.004, 0.070] and ß = 0.125, 95% CI [0.031, 0.219], respectively). Visceral adipose tissue (VAT) was associated with reduced spine mobility (BASMI: ß = 0.20, 95% CI [0.07, 0.33]). Additionally, increase in VAT and fat mass parameters was linked to worse disease activity and functional disability in women, while they were strongly associated with reduced spinal mobility in men. Conclusion: Higher levels of body fat and VAT were positively associated with increased disease activity, functional disability, and reduced spinal mobility in patients with radiographic axSpA treated with bDMARDs.


  • Open Access

    Comparing clinical profiles in spondyloarthritis with Crohn’s disease or ulcerative colitis: insights from the ASAS-PerSpA study

    by Valeria Rios Rodriguez, Tugba Izci Duran, Murat Torgutalp, Clementina López-Medina, Maxime Dougados, Mitsumasa Kishimoto, Keisuke Ono, Mikhail Protopopov, Hildrun Haibel, Judith Rademacher, et al.

    Objectives: Assuming SpA manifestations may vary among patients with different inflammatory bowel disease (IBD) subtypes, we explored the clinical characteristics associated with the presence of Crohn’s disease (CD) or ulcerative colitis (UC) in patients with spondyloarthritis (SpA). Methods: We included 3152 patients of ASAS-PerSpA study diagnosed with either axial SpA or peripheral SpA, according to their treating rheumatologist. Of these, 146 (4.6%) had confirmed IBD by endoscopy and were categorized into CD or UC groups. Demographics, clinical characteristics, treatments and patient-reported outcomes were compared between the two subgroups. Results: From 146 patients included in the current analysis, 87 (59.6%) had CD [75 (86.2%) axial SpA and 12 (13.8%) peripheral SpA], and 39 (26.7%) had UC [34 (87.2%) axial SpA and 5 (12.8%) peripheral SpA]. CD and UC groups had similar age with average of 44.9 (13.5) vs 44.0 (13.0) years, respectively, and a slight male predominance in CD (63.2%) compared with UC (51.3%). Diagnostic delay for SpA was 7.0 (6.9) years for CD and 8.8 (8.1) years for UC. Chronic back pain was the most reported symptom present in 95.4% of CD patients and 89.7% of UC patients. Both groups had similar musculoskeletal phenotyping, with higher frequency of psoriasis (15.4%) and uveitis 28.2% in UC; and higher tendency to be HLA-B27 positive in CD (51.9% in CD vs.s 39.4% in UC). Conclusion: In our analysis patients with SpA and concurrent CD or UC had mainly similar musculoskeletal phenotypes. However, they differ slightly in extra-musculoskeletal manifestations and HLA-B27 prevalence.


  • Open Access

    Self-reported diagnostic confidence predicts diagnostic accuracy in axial spondyloarthritis imaging

    by Sevtap Tugce Ulas, Felix Radny, Katharina Ziegeler, Iris Eshed, Juliane Greese, Dominik Deppe, Carsten Stelbrink, Robert Biesen, Hildrun Haibel, Valeria Rios Rodriguez, et al.

    Reporting diagnostic confidence (DC) in axial spondyloarthritis (axSpA) imaging is recommended by the ASAS guidelines. Our aim was to investigate whether self-reported DC predicts diagnostic accuracy in axSpA imaging using X-ray (XR), computed tomography (CT) and magnetic resonance imaging (MRI). We performed a post hoc analysis including 163 patients with low back pain (89 axSpA and 56 non-axSpA). Nine blinded readers with different experience levels [inexperienced (12 years)] scored the sacroiliac joint images for compatibility with axSpA. DC was reported on a scale from 1 (not sure) to 10 (very sure). Mean DC scores and standard deviations were calculated for correct and incorrect responses using XR, CT, MRI, XR+MRI and CT+MRI. Differences in DC were assessed using the Mann–Whitney U test. DC scores were higher for correct axSpA diagnoses and differed significantly between correct and incorrect responses for all modalities (P < 0.001), with a mean DC of 7.1 ± 2.1 and 6.3 ± 2.1 for XR, 8.3 ± 1.8 and 6.7 ± 2.0 for CT, 8.1 ± 1.9 and 6.2 ± 1.9 for MRI, 8.2 ± 1.8 and 6.7 ± 1.8 for XR+MRI and 8.4 ± 1.8 and 6.8 ± 1.8 for CT+MRI, respectively. This was also the case when looking at the results by experience group, except for XR in the inexperienced group. Providing self-reported DC in radiological reports is useful information to predict diagnostic reliability in axSpA imaging.